Eva C. Jensen - Concepedia

Author

Eva C. Jensen

AstraZeneca (Sweden)

Also Known As

Assen Goudev, E. C. Jensen, E. Jensen, Eva C Jensen, Eva C. Jensen, Eva Jensen, Evan J Jensen, Evan J. Jensen

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (Sweden)Brigham and Women's Hospital Thrombolysis in Myocardial Infarction Study Group University of Sheffield Université Paris Cité

About

Eva C. Jensen is an author at AstraZeneca (Sweden) specializing in medicine, anesthesiology, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	787
2	Cardiothoracic Surgery	4	4	141
3	Pharmacology	3	3	193
4	Pediatric Surgery	1	1	34
5	Perioperative Medicine	1	1	54

Eva C. Jensen

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction Marc P. Bonaca, Deepak L. Bhatt, Marc Cohen, New England Journal of Medicine	2015	1.9K
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease Marc P. Bonaca, Deepak L. Bhatt, Robert F. Storey, Journal of the American College of Cardiology ThrombosisHeart FailureCardiovascular DiseaseAtherosclerosisMedicine	2016	383
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y <sub>12</sub> inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 Marc P. Bonaca, Deepak L. Bhatt, Philippe Gabríel Steg, European Heart Journal	2015	164
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events Marc P. Bonaca, Deepak L. Bhatt, Ton Oude Ophuis, JAMA Cardiology	2016	97
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists Gregory Y.H. Lip, Lars Hvilsted Rasmussen, Sandra Olsson, European Heart Journal	2009	94
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran Giancarlo Agnelli, Bengt I. Eriksson, Alexander T. Cohen, Thrombosis Research ThrombosisMedicineAnticoagulantPharmacotherapySafety Assessment	2008	94
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial Giulia Magnani, Robert F. Storey, Philippe Gabríel Steg, European Heart Journal	2015	82
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54 Marc P. Bonaca, Robert F. Storey, Pierre Théroux, Journal of the American College of Cardiology Prior MiPegasus-timi 54MedicinePharmacologyClinical Trials	2017	80
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease Sameer Bansilal, Marc P. Bonaca, Jan H. Cornel, Journal of the American College of Cardiology ThrombosisMultivessel Coronary DiseaseCardiovascular DiseaseSecondary PreventionVascular Surgery	2018	70
A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients L. Lindholm, Martin Westerberg, Anders Bengtsson, The Annals of Thoracic Surgery Closed Perfusion SystemCardiothoracic SurgeryHeparin CoatingElderly PatientsMechanical Circulatory Support	2004	54

Page 1